ten23 health, a global contract development and manufacturing organization (CDMO), has expanded swissfillon’s manufacturing site in Visp, canton of Valais, Switzerland, which was acquired last October.
 
The FDA-inspected site in Visp currently offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and market supplies. To enable further growth of its existing production capacity, ten23 health is investing in an expansion of supporting areas in an adjacent building.
 
This expansion will provide an additional 1000 square meters of clean-room space for visual inspection and cold storage and also include clean-room space for additional services, such as supporting device assembly operations and labeling and secondary packaging. The size of the investment is not disclosed.
 
Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health, commented, “Only five months ago, swissfillon joined ten23 health. This first expansion of the footprint in Visp is a strong commitment to our location in the Valais as well as Switzerland and a testimonial of the competent and experienced team at Visp. Furthermore, it is an important step in our long-term strategy to expand our manufacturing capacity for complex sterile dosage forms for our customers and their patients.”
 
swissfillon, a leader in the sterile filling of complex pharmaceuticals, was acquired by ten23 health in October 2021. ten23 health’s combination of pharmaceutical development services with clinical and commercial fill & finish services offers clients an end-to-end set of capabilities. 
 
ten23 health launched its operations in Basel, Switzerland, in September 2021, with 4000 square meters of lab and office space, providing a work environment for up to 150 colleagues. Benefiting from the talented workforce in the Basel area, ten23 health has built up a team of accomplished leaders, scientists, and technicians over recent months.